SK bioscience Co.,Ltd. 302440.KS · Stock Open SK bioscience Co.,Ltd. in new tab
SK bioscience Co.,Ltd. Analysis (302440.KS)
Is SK bioscience Co.,Ltd. a good investment? SK bioscience Co.,Ltd. (302440.KS) is currently trading at 40300.00 KRW. Market analysts have a consensus price target of 37200.00 KRW. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: SK bioscience Co.,Ltd. is expected to release its next earnings report on July 24, 2026.
Investor FAQ
Does SK bioscience Co.,Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is SK bioscience Co.,Ltd.?
SK bioscience Co.,Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 24, 2026.
Company Profile
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.
Community Discussion